Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
University of British Columbia · BC Cancer Agency · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
731
total citations
- FWCI
- 65.03
- Percentile
- 100%
- References
- 29
Citations per year
Authors
10- WMWilliam MorrisCorresponding
University of British Columbia, BC Cancer Agency
- STScott Tyldesley
BC Cancer Agency, University of British Columbia
- SRS. Rodda
University of British Columbia
- RHRoss Halperin
University of British Columbia, BC Cancer Agency
- HPHoward Pai
University of British Columbia, BC Cancer Agency
Topics & keywords
Topics
Keywords
- Medicine
- Clinical endpoint
- Prostate cancer
- Brachytherapy
- Hazard ratio
- Randomized controlled trial
- Androgen deprivation therapy
- Urology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.